Compare iShares MSCI Japan ETF (EWJ) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Japan ETF trades at $97.88 (market cap $23.87B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M). The key difference: iShares MSCI Japan ETF is far larger — about 212.8× Inovio Pharmaceuticals Inc's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EWJ | INO | |
|---|---|---|
Market Cap | $23.87B | $112.19M |
Volume | 5,412,820 | 3,201,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $2.65 |
52-Week Low | $78.36 | $0.66 |
Typical Hold Time | 56 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.76, down 0.57% on the day amid mixed technical signals with a neutral overall rating. The ETF faces headwinds from Japan's monetary policy uncertainty as the Bank of Japan continues its tightening cycle, while benefiting from international equity outperformance trends in 2026. Technical indicators show the ETF trading near pivot point resistance at $98 with support at $97.
The outlook remains balanced with potential upside from Japan's AI and semiconductor exposure offset by currency volatility and rising bond yields. Key risks include yen fluctuations and global rate pressures, while institutional interest in Japanese equities provides support. The ETF's performance will hinge on BOJ policy effectiveness and sustained international market strength.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
